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Myeloid differentiation factor-88/interleukin-1 signaling controls
cardiac fibrosis and heart failure progression in inflammatory
dilated cardiomyopathy
Abstract
RATIONALE: The myeloid differentiation factor (MyD)88/interleukin (IL)-1 axis activates
self-antigen-presenting cells and promotes autoreactive CD4(+) T-cell expansion in experimental
autoimmune myocarditis, a mouse model of inflammatory heart disease. OBJECTIVE: The aim of this
study was to determine the role of MyD88 and IL-1 in the progression of acute myocarditis to an
end-stage heart failure. METHODS AND RESULTS: Using alpha-myosin heavy chain peptide
(MyHC-alpha)-loaded, activated dendritic cells, we induced myocarditis in wild-type and MyD88(-/-)
mice with similar distributions of heart-infiltrating cell subsets and comparable CD4(+) T-cell
responses. Injection of complete Freund's adjuvant (CFA) or MyHC-alpha/CFA into diseased mice
promoted cardiac fibrosis, induced ventricular dilation, and impaired heart function in wild-type but not
in MyD88(-/-) mice. Experiments with chimeric mice confirmed the bone marrow origin of the
fibroblasts replacing inflammatory infiltrates and showed that MyD88 and IL-1 receptor type I signaling
on bone marrow-derived cells was critical for development of cardiac fibrosis during progression to
heart failure. CONCLUSIONS: Our findings indicate a critical role of MyD88/IL-1 signaling in the
bone marrow compartment in postinflammatory cardiac fibrosis and heart failure and point to novel
therapeutic strategies against inflammatory cardiomyopathy.
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Abstract 
Rationale: The MyD88/IL-1 axis activates self-antigen presenting cells and promotes 
autoreactive CD4+ T cell expansion in experimental autoimmune myocarditis, a mouse 
model of inflammatory heart disease. 
Objective: The aim of this study was to determine the role of MyD88 and IL-1 in the 
progression of acute myocarditis to an end stage heart failure. 
Methods and Results: Using alpha-myosin heavy chain peptide (MyHC-α)-loaded, 
activated dendritic cells, we induced myocarditis in wild-type and MyD88-/- mice with 
similar distributions of heart-infiltrating cell subsets, and comparable CD4+ T cell 
responses. Injection of complete Freund’s adjuvant (CFA) or MyHC-α/CFA into 
diseased mice promoted cardiac fibrosis, induced ventricular dilation and impaired heart 
function in wild-type, but not in MyD88-/- mice. Experiments with chimeric mice 
confirmed the bone marrow origin of the fibroblasts replacing inflammatory infiltrates 
and showed that MyD88 and IL-1 receptor type I signalling on bone marrow-derived 
cells was critical for development of cardiac fibrosis during progression to heart failure.  
Conclusion: Our findings indicate a critical role of MyD88/IL-1 signalling in the bone 
marrow compartment in post-inflammatory cardiac fibrosis and heart failure, and point to 
novel therapeutic strategies against inflammatory cardiomyopathy. 
 
Key words: autoimmune myocarditis, heart failure, fibrosis, innate immunity 
 
Non-standard Abbreviations and Acronyms: APC - antigen presenting cell, BM - bone 
marrow, bmDC - bone marrow-derived dendritic cell, CFA - complete Freund’s adjuvant, 
EAM - experimental autoimmune myocarditis, MyHC-α - alpha-myosin heavy chain, 
OVA - ovalbumine, TLR - Toll-like receptor 
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Introduction 
Inflammatory cardiomyopathy refers to a subtype of dilated cardiomyopathy, a 
common cause of heart failure in young adults1. Inflammatory cardiomyopathy often 
results from infection-triggered myocarditis, and is characterized by impaired cardiac 
contractility, ventricular dilation, and progressive myocardial fibrosis2,3. Many viruses but 
also bacteria, parasites, drugs, and systemic diseases are supposed to trigger cardiac 
inflammation. It is not clear yet, how these different etiologic agents promote the 
progression of acute cardiac inflammation to a common final pathway of end stage heart 
failure with a common morphological phenotype. 
Clinical observations and animal experiments suggest that autoimmunity plays an 
important role in inflammatory cardiomyopathy4-7. In the experimental autoimmune 
myocarditis (EAM) model, disease development depends on the sequential activation of 
self-antigen presenting cells (APCs) and the expansion of autoreactive, heart-specific 
CD4+ T cells7-11. We found that cardiac damage of any cause, together with non-specific 
activation of APCs via Toll-like receptors (TLRs) is sufficient to break 
immunotolerance12,13. Accordingly, activated bone marrow-derived dendritic cells 
(bmDCs) loaded with alpha-myosin heavy chain (MyHC-α) peptide induce acute CD4+ T 
cell mediated myocarditis in susceptible mice12,13. IL-1 receptor and most of the TLRs 
share the common downstream signalling adaptor molecule MyD8814,15. MyD88- and IL-
1R-signalling on APCs are critical for the induction of heart-specific T cell responses and 
EAM. However, adoptive transfer of wild-type bmDC with intact IL-1R/MyD88 
signalling restores myocarditis susceptibility of MyD88-/- and IL-1R-/- mice13,16. 
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These observations might explain, why different etiologic agents can induce acute 
cardiac inflammation in susceptible individuals. However, it does not explain how 
pathological remodelling and dilated cardiomyopathy develop after resolution of 
inflammation in some of the affected hearts. In humans, dilation of the left ventricle, and 
cardiac fibrosis are hallmarks of end-stage congestive heart failure. Enhanced cardiac 
fibrosis results in a restrictive diastolic filling pattern, which is indicative of a poor 
prognosis. In the EAM model, similar to the observations in humans, myocarditis largely 
resolves and some mice develop fibrosis, ventricular dilation and impaired fractional 
shortening12,17-19. 
Here, we provide evidence that progression of EAM into an end stage heart 
failure phenotype depends on the sequential activation of MyD88- and IL-1R-dependent 
signalling pathways in the inflammatory bone marrow (BM)-derived cell compartment. 
Furthermore, we introduce a novel approach to induce accelerated heart failure and 
cardiac fibrosis in a mouse model of inflammatory heart disease. 
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Materials and Methods 
Mice BALB/c (n=125), MyD88-/- (n=60), IL-1R-/- (n=17) mice (maintained on a BALB/c 
background as described previously13,16) and C57BL/6-EGFP transgenic mice (EGFP 
under the control of the β-actin promoter) backcrossed into BALB/c background for >10 
generations (hereafter referred to as BALB/c-EGFP, n=8) were used at 6-8 week of age. 
Animal experiments were performed in accordance with the Swiss federal law and were 
approved by the local authorities. 
 
Chimeric mice 6-8 week old mice were lethally irradiated with two doses of 6.5 Gy as 
described11 and transplanted with total of 2x107 crude BM cells from BALB/c, BALB/c-
EGFP, MyD88-/- or IL-1R-/-. Chimeric mice were used 6 weeks after BM reconstitution. 
 
Immunization protocols Myocarditis was induced by bmDCs, as described12,13. Briefly, 
immature bmDCs were pulsed with 10 µg/mL MyHC-α614-634 (Ac-
SLKLMATLFSTYASAD-OH) or ovalbumine (OVA323-339) peptide, activated with 0.1 
µg/mL lipopolysaccharide and 5 µg/mL anti-CD40 prior to intraperitoneal injection of 
5x105 cells/mouse at days 0, 3 and 5. In the respective experiments, mice received 
additional subcutaneous injections of 200 µL PBS or CFA emulsified with PBS (1:1) 
with or without 100 µg MyHC-α at days 10 and 17. In some experiments, bmDC 
immunized mice were repetitively, every second day, injected with 1 µg/ml 
lipopolysaccharide (Escherichia coli 0111:B4; Sigma), 10 µM CpG-ODN or 10 µg/ml 
peptidoglycan (Staphylococcus aureus; Fluka) for 14 days. 
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Recombinant mouse IL-1β (R&D Systems) was injected intraperitoneally at 20 µg/kg in 
PBS at days 13, 17, 21 and 25 in the respective experiments.  
 
Histopathology Myocarditis severity was scored on hematoxylin-eosin stained heart 
sections using a semi-quantitative 0-4 scale (see Supplementary on-line material). 
Masson’s trichrome staining was used to detect fibrosis. The degree of fibrosis was 
calculated as % of the fibrotic area in relation to the total heart area using analySIS FIVE 
software (Olympus). 
 
Flow cytometry Heart inflammatory cells and splenocytes were isolated and processed as 
described11,19. Cells were stained using fluorochrome-conjugated mouse-specific 
antibodies against CD45, CD11b, CD11c, CD4, Gr-1, F4/80, IFN-γ, IL-4 and IL-17 (all 
BD Pharmingen). For intracellular cytokine stainings, cells were stimulated for 4 h with 
50 ng/mL phorbol myristate acetate and 500 ng/mL ionomycin in the presence of 10 
µg/mL Brefeldin A (all Sigma-Aldrich). Heart infiltrates were identified as CD45+ cells 
from heart tissue suspensions gated on CD45/forward scatter plots as described11. 
 
Proliferation assay CD4+ T cells were purified using magnetic beads (CD4+ T cell 
isolation kit; Miltenyi Biotec). A total of 2x105 splenocytes or 5x104 CD4+ T cells co-
cultured with 105 irradiated (25 Gy) syngeneic splenocytes were re-stimulated for 48 h in 
the presence of sequential dilutions of the MyHC-α or OVA peptide. Proliferation was 
assessed by measuring [3H]-thymidine incorporation during the last 8 hours. 
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Real-Time RT-PCR RNA isolation, mRNA transcription and PCR were performed as 
described11,19. Oligonucleotides complementary to transcripts of the genes analyzed are 
listed in the supplementary on-line material. Transcript levels of gapdh were used as 
endogenous reference. 
 
Isolation and culture of cardiac fibroblasts Cardiac fibroblasts were isolated and 
cultured as described20 with minor modifications (for details see supplementary on-line 
material). 
 
Immunocytochemistry Hearts were formalin-fixed and paraffin-embedded and cells were 
fixed with 4% paraformaldehyde. Immunostaining procedures were performed as 
described19. Sections and cells were stained with rat anti-mouse CD45 (BD Pharmingen), 
rabbit anti-mouse fibronectin (Millipore) and goat anti-rabbit IgG Alexa Fluor 546 
(Invitrogen). Nuclei were detected using DAPI (Pierce). 
 
Echocardiography Transthoracic echocardiography was performed using a 30 MHz 
probe and the Vevo 770 Ultrasound machine (VisualSonics). Detailed description is 
available in the supplementary on-line material. 
 
Statistics All data, except for the myocarditis severity scores, were considered as 
normally distributed and analyzed by unpaired, two-tailed Student’s t-test, and for 
multiple comparisons by one-way or two-way ANOVA followed by Bonferroni's post-
test. Severity scores were analyzed by the two-tailed Mann-Whitney U test, and for 
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multiple comparisons by the Kruskal-Wallis one-way analysis. Differences were 
considered as statistically significant for p<0.05. 
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Results 
CFA challenging promotes massive cardiac fibrosis in mice with EAM 
To study the potential role of TLR activation on the progression of acute 
myocarditis to inflammatory cardiomyopathy, we induced acute myocarditis using heart-
specific peptide (MyHC-α)-loaded bmDCs and boosted diseased mice with CFA, a non-
specific, strong TLR stimulant known to activate various TLR receptors21. As illustrated 
in Figure 1, MyHC-α-, but not OVA-loaded, bmDC immunized BALB/c mice developed 
myocarditis with CD45+ inflammatory infiltrates in the myocardium and heart-specific 
autoreactive CD4+ T cell responses at day 10 after the first bmDC injection (Figs. 1A-H). 
To specifically address the effects of CFA challenge on disease progression, we injected 
groups of MyHC-α-loaded bmDC immunized mice with either CFA or PBS at days 10 
and 17, and analyzed their hearts at day 34. CFA but not sham challenged mice 
developed massive fibrosis (Figs. 1I,J). The fibrotic phenotype in CFA challenged mice 
was consistently detected 120 days after bmDC immunization (data not shown). 
Importantly, CFA alone was not sufficient to induce any detectable fibrotic response at 
day 34 in OVA-loaded bmDCs immunized mice (Fig. 1K).  
CFA represents a non-specific TLR stimulant. To clarify the role of specific TLRs 
in the progression of myocardial fibrosis, mice with acute myocarditis were boosted 
repetitively with selective TLR2- (i.e. peptidoglycan), TLR4- (i.e. lipopolysaccharide) or 
TLR9-agonists (i.e. CpG), starting at day 10 post-immunization and the percentages of 
the fibrotic areas at day 34 were analyzed. As illustrated in Suppl. Fig. 1, hearts of TLR 
stimulant, but not sham treated mice showed significant fibrotic areas within their hearts. 
Compared with the massive fibrosis observed after CFA stimulation, the effects of 
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repetitive TLR stimulant injections were modest albeit significantly higher compared 
with sham treatments.  
 
MyHC-α-loaded bmDC induce similar EAM phenotypes in wild-type and MyD88-/- 
mice 
Given the integrating role of the adaptor molecule MyD88 in various TLR 
pathways, we investigated the specific role of MyD88 signalling in the fibrotic response 
following acute myocarditis. As reported previously12,13 and illustrated in Figure 2, 
immunization with self-antigen-loaded wild-type bmDCs induce myocarditis of 
comparable severity in wild-type and MyD88-/- mice at day 10 (Figs. 2A,B). Importantly, 
we did not detect fibrotic areas in inflamed hearts of both mouse strains at this time point 
(Suppl. Fig. 2). Furthermore, gene expression analysis showed no differences in the 
cardiac mRNA levels of pro-inflammatory cytokines such as, ifn-γ, il-4, il-17, il-33, ccl1, 
mcp-1, mip-1α, mip-1β and mip-2 (Suppl. Fig. 3) between wild-type and MyD88-/- mice. 
To investigate whether the distributions of the major heart-infiltrating cell subsets differ 
between wild-type and MyD88-/- mice, heart-infiltrating CD45+ cells were analyzed by 
flow cytometry. As shown in Fig. 2C, we found no differences in the distribution of 
monocytes (CD11b), granulocytes (Gr-1), macrophages (F4/80), CD4+ T cells (CD4), and 
DCs (CD11c) within the CD45+ heart-infiltrating cell subsets between wild-type and 
MyD88-/- mice at day 10 after bmDC immunization. 
Next, we compared the autoreactive CD4+ T cell responses in immunized wild-
type and MyD88-/- mice. CD4+ T cells were isolated at day 10 from spleens of wild-type 
and MyD88-/- mice immunized with activated, MyHC-α loaded bmDCs and re-stimulated 
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in the presence of APCs and sequential dilutions of the MyHC-α peptide. As 
demonstrated, both wild-type and MyD88-/- CD4+ T cells showed similar proliferation 
responses upon MyHC-α peptide stimulation (Fig. 2D). In addition, we found no 
differences in the percentages of IFNγ-, IL-4- and IL-17-producing CD4+ T cell subsets 
between diseased wild-type and MyD88-/- mice (Fig. 2E). Thus, immunization with 
bmDCs induced the same myocarditis phenotype regarding prevalence, severity of 
inflammation, distribution of heart infiltrating cells, and CD4+ T cell responses in wild-
type and MyD88-/- mice. 
 
MyD88-/- mice are protected from fibrosis and heart failure  
As illustrated above, CFA greatly accelerates cardiac fibrosis in the EAM model. 
To define the role of MyD88 signalling in the fibrotic response and its effects on the 
development of an end stage heart failure phenotype, wild-type and MyD88-/- mice were 
immunized with MyHC-α loaded, activated WT bmDCs and challenged with either CFA 
or MyHC/CFA at days 10 and 17. Wild-type, but not MyD88-/- mice developed severe 
cardiac fibrosis at day 34 (Fig. 3A) and 42 (Fig. 4H) respectively. Development of 
cardiac fibrosis was associated with massive dilation of the left ventricle, increased 
heart/body weight ratios (Figs. 4D-F), and severely impaired cardiac functions in wild-
type, but not MyD88-/- mice (Fig. 5A,B) reflecting an end-stage heart failure phenotype. 
Mirroring the profound fibrotic response, wild-type, but not MyD88-/- mice showed 
marked diastolic dysfunction, i.e. a restrictive left ventricular filling pattern reflected by 
an increase in the E/A inflow pattern (Figs. 5C-E).  
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Persistent heart-specific T cell responses do not explain cardiac fibrosis in wild-type 
mice  
So far, our findings suggest that both heart specific autoimmunity and MyD88 
signalling are critical for cardiac fibrosis and heart failure progression. The question 
therefore arises, whether these phenotypes reflect differences in auto-reactive, heart-
specific T cells responses between MyD88-/- and wild-type mice during the late phases of 
disease. This, however, seems not to be the case, because most cardiac infiltrates resolved 
as early as at day 21 in both, MyD88-/- and wild-type mice after CFA challenge (Fig. 6A 
and Suppl. Fig. 2). In wild-type mice, inflammatory cells were replaced by fibrotic tissue 
at this stage. Moreover, we found the same in vitro proliferation response of MyHC-α-
specific CD4+ T cells isolated at late time points from spleens of MyD88-/- mice without 
vs. wild-type mice with myocardial fibrosis (Fig. 4B).  
On the other hand, if bmDC-immunized mice were boosted not only with CFA, 
but also with the antigenic MyHC-α peptide, we observed persistence of the myocarditis 
phenotype and marked inflammatory infiltrates without detectable fibrosis in both, wild-
type and MyD88-/- hearts up to day 21 (Fig. 4A-C). Despite the ongoing recruitment of 
inflammatory cells to the hearts, MyD88-/- mice were protected from the development of 
massive cardiac fibrosis, ventricular dilation and heart failure at day 42 (Figs. 4D,E,G). 
These findings indicate that the presence of an ongoing auto-reactive T cell 
response by itself does not automatically induce a fibrotic response and development of 
an end-stage heart failure phenotype.   
 
IL-1β  mediates myocardial fibrosis  
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IL-1 is a key pro-inflammatory cytokine produced in response to TLR/MyD88 
stimulation22. Next, we specifically address the role of IL-1 signalling in tissue fibrosis. 
Accordingly, we challenged WT bmDC immunized MyD88-/-, IL-1R-/-, and WT control 
mice with CFA, analyzed the expression of pro-fibrotic genes in heart tissues, and 
assessed the extent cardiac fibrosis on follow up.  
Similar to MyD88-/- mice, but in contrast to wild-type animals, IL-1R-/- mice were 
completely protected from cardiac fibrosis at day 34 (Fig. 3A). Real-Time RT-PCR 
analysis revealed elevated expression of il-6, and collagen as well as several genes 
known to be directly involved in tissue remodelling, such as mmp-8, mmp-9, timp-2 and 
timp-3 at day 21 (Fig. 7) in wild-type, but not in MyD88-/- and IL-1R-/- mice. These results 
correlate with the fibrotic phenotype observed at day 34 (Fig. 3A). However, there was 
no correlation between the fibrotic phenotype and cardiac mRNA transcript levels of il-
33, tgf-β1, tnf-α, sdf-1, mmp-2 and timp-1 (Fig. 7). CFA challenge up-regulated the 
expression of il-1β in wild-type and IL-1R-/- but not in MyD88-/- mice (Fig. 7). This 
observation suggests that CFA triggered il-1β expression depends on MyD88 signalling 
in our model. Furthermore, our data imply that the MyD88-IL-1 axis is critical for the 
progressive tissue fibrosis, which parallels the transition of acute myocarditis to an end 
stage heart failure. Accordingly, treatment of bmDC immunized wild-type mice with IL-
1β alone was sufficient to promote cardiac fibrosis and heart failure at day 34 (Fig. 3B), 
but did not enhance cardiac inflammation at day 21 (Suppl. Fig. 4). In contrast, IL-1β 
treatments did not mediate cardiac fibrosis in MyD88-/- or IL-1R1-/- mice (not shown). 
 
MyD88/IL-1 signalling in the BM-derived cellular compartment mediates fibrosis 
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The BM represents the dynamic source of heart-infiltrating fibroblast progenitors 
in EAM23. We therefore created chimeric mice to address the specific role of BM-derived 
cells in heart failure progression and tissue fibrosis. All chimeric mice were immunized 
with bmDCs, and for fibrosis development animals were challenged with MyHC/CFA. In 
chimeric mice reconstituted with EGFP+ BM, nearly all EGFP+ cells were CD45+ 
suggesting an inflammatory phenotype in the acute phase (d10, Figs. 8A,B). At day 42, 
however, we found many EGFP-positive signals in the fibronectin-positive fibrotic tissue 
(Figs. 8C,D), and in cardiac fibroblasts expanded from fibrotic hearts (Fig. 8E). This 
implicates that BM-derived cells represent the major cellular substrate of cardiac fibrosis 
in our model. Next, we specifically addressed the role of MyD88/IL-1 signalling in the 
BM-derived cellular compartment for cardiac fibrosis and heart failure progression. As 
shown in Figure 8, wild-type mice reconstituted with MyD88-/- (MyD88-/-->WT) or IL-
1R-/- (IL-1R-/-->WT) BM did not develop significant fibrosis, in contrast to control mice 
reconstituted with wild-type BM (WT->WT, Fig. 8G). Instead, reconstitution of MyD88-/- 
or IL-1R-/- mice with wild-type BM (WT->MyD88-/- and WT->IL-1R-/- respectively) was 
sufficient to induce severe fibrosis in our model (Fig. 8G). Furthermore, increased 
heart/body weight ratios indicated ventricular dilatation and an end stage heart failure 
phenotype (Fig. 8H). Taken together, these data indicate that MyD88/IL-1 signalling in 
the BM-derived cellular compartment is critical for myocardial fibrosis and development 
of end stage heart failure in inflammatory cardiomyopathy. 
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Discussion 
Our data show for the first time the relevance of the MyD88/IL-1 axis in the 
progression of EAM to end stage heart failure, thereby illustrating its critical role in 
cardiac fibrosis. Obviously, non-specific activation of the IL-1-MyD88 axis is sufficient 
for heart failure progression once the heart experienced an acute inflammatory injury, and 
neither the presence of a specific pathogen nor the persistence of a dominant heart-
specific T cell response are required for the development of a typical end stage heart 
failure phenotype. 
Simply assessing myocarditis susceptibility of transgenic animals lacking defined 
components of the innate immune system does not allow a conclusion regarding their 
specific role at different time points during induction or progression of disease. Mice 
lacking MyD88, for example, are protected from both, autoimmune and viral myocarditis 
due to impaired virus replication and APCs function13,24. However, the combined 
challenging with bmDC immunization and CFA, offers an attractive strategy to overcome 
myocarditis resistance and to address the relevance of this specific genetic effect on heart 
failure progression. From clinical perspective, the identification of innate mediators 
promoting heart failure progression at later phases of the disease is of prime importance, 
as it may allow us to identify novel drug targets against heart failure. 
Our data demonstrate that progression of myocarditis to cardiac fibrosis requires 
both, prior cardiac inflammation and an additional non-specific adjuvant effect promoting 
IL-1 release. TLRs serve as central targets for various immune stimulating adjuvants21 
and induce the activation of several pro-inflammatory genes, including il-1β. Clinical 
data suggest a role for TLR4 signalling in end stage heart failure. Similarly, 
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coxsackievirus represents a common infective agent promoting post-inflammatory 
cardiomyopathy in Western countries that directly activates the immune system through 
TLRs. In animal experiments, TLR4-deficient mice indeed show reduced disease severity 
and fibrosis in a mouse model of coxsackievirusB3-induced myocarditis25. In the 
commonly used EAM model, successful immunization with heart-specific self-antigen 
always requires co-stimulation with the non-specific adjuvant CFA. Our data indicate that 
CFA co-stimulation is not only required for the priming of autoreactive T cells but also 
promotes cardiac fibrosis independently of the autoreactive T cell response. In addition, 
our findings may explain the marked fibrosis that is consistently observed in MyHC-
α/CFA or coxsackievirusB3 immunized mice and the less pronounced fibrosis after 
immunization with self-antigen loaded bmDCs12,26,27. 
Mechanistically, MyD88 signalling confers the activation of pro-inflammatory 
genes, including il-1β. Activation of the IL-1 type 1 receptor on the other hand, also 
mediates its effects trough the downstream adaptor molecule MyD88. In our model, 
delivery of the cytokine IL-1β alone was sufficient to promote cardiac fibrosis in the 
bmDC-immunized mice. IL-1R signalling regulated the expression of pro-fibrotic genes 
including mmp-8 and -9, timp-2, -3 and -4 and collagen. These findings are in line with 
observations that MMPs and TIMPs play an important role in myocarditis and 
myocardial remodelling27-29. In addition, Bujak et al. reported that IL-1 signalling on 
cardiac fibroblasts regulates MMPs and TIMPs expression30. Furthermore, MyD88/IL-1 
signalling has been shown to be essential for the development of fibrosis in bleomycin-
induced lung injury31, collagen-induced arthritis32, as well as in the healing processes after 
myocardial infarction30 and in the vascular remodelling33. 
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Regarding the EAM model, IL-1 signalling apparently plays a dual role. On the 
one hand, it mediates activation of APCs and expansion of the self-pathogenic heart-
specific CD4+ T cell subset promoting myocarditis16,34, on the other hand it promotes 
fibrosis and heart failure progression at later stages of disease. This idea might explain 
why increased levels of il-1β transcripts in the myocardium show a linear correlation with 
cardiac function in coxsackievirus-mediated murine myocarditis35, and the observation 
that the local expression of an IL-1R antagonist improves survival in the same model36. 
In our model, the MyD88-dependent signalling appears to be the principle 
mediator of the development of post-inflammatory heart failures. The combination of the 
CFA challenge with a boost of the self-peptide enhanced myocarditis severity in both 
wild-type and MyD88-/- mice, but was insufficient to induce fibrosis the end stage heart 
failure phenotype in MyD88-/- mice. This is important, given the fact that functional 
impairment and elevated levels of pro-fibrotic mediators directly correlate with the extent 
of the inflammatory infiltrates17,27,28,37,38. Obviously, acute cardiac inflammation is 
required, but not sufficient for the development of myocardial fibrosis and heart failure 
progression.  
Experiments with chimeric mice indicate a decisive role of the BM compartment 
as major substrate of cardiac fibrosis. Our observations clearly show that the heart failure 
phenotype depends on functional MyD88/IL-1 signalling in the BM-derived 
compartments only. Given the BM-derived cellular compartment represents the primary 
infiltrating cells into the heart during acute myocarditis, our data strengthens previous 
observations correlating the extent of heart failure to the level of cardiac infiltrates. Thus, 
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our data clearly identify the BM-derived cellular compartment as a potential target for 
therapeutic interventions in end-stage heart failure. 
Does that mouse system mirror human inflammatory dilated cardiomyopathy? 
Divergence of the post-inflammatory fibrotic response found in our model is also 
observed in humans. Furthermore, several lines of evidence indicate that tissue damage 
promotes the release of endogenous TLR activators such as heat-shock proteins, for 
example. Consequently, ongoing TLR stimulation might contribute and promote the 
development of tissue fibrosis and heart failure. Clinical observations suggest that 
infections further enhance cardiac dysfunction in patients with severe heart failure. In 
addition up-regulation of TLR as well as pro-fibrotic genes are hallmarks of heart failure 
in humans39,40. These facts suggest, that indeed, TLR signalling might enhance heart 
failure in inflammatory cardiomyopathy in humans as well. 
Taken together, we found that activation of the MyD88/IL-1 axis is critical for 
tissue fibrosis and heart failure progression in inflammatory cardiomyopathy Given 
findings from clinical long-term follow up studies on humans with acute myocarditis 
demonstrating spontaneous improvement in 40-70% of patients and progression to dilated 
cardiomyopathy in 21% of patients41, we can only speculate how the interplay of genetic 
and environmental factors orchestrate the individual susceptibility for the progression of 
myocarditis to end-stage heart failure42. In this regard, our findings warrant a closer focus 
on the innate immune system in general, and in particular, the role of MyD88/IL-1 axis 
during this process. Finally, our findings suggest targeting the MyD88/IL-1 axis as a 
novel treatment strategy for patients with inflammatory dilated cardiomyopathy.  
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Figure legends 
Figure 1 
CFA promotes myocardial fibrosis after myocarditis.  
MyHC-α-loaded bmDCs induce myocarditis (B) with massive infiltration of CD45+ cells 
(E) at day 10, whereas mice injected with PBS (A,D) or with OVA-loaded bmDCs (C,F) 
showed no sign of cardiac inflammation and (A,C) and very few CD45+ cells in the 
myocardium (D,F). To assess antigen-specific T cell responses, CD4+ T cells were 
isolated from mice immunized with MyHC-α- (open circles) or OVA-loaded (filled 
circles) bmDCs at day 10 and in vitro re-stimulated with MyHC-α (G) or OVA (H) 
peptides on irradiated syngeneic splenocytes for 48 hours. Data represent mean ± SD of 
triplicates from one out of three independent experiments.  
Heart tissue sections were stained with Masson’s trichrome and analyzed for fibrosis at 
day 34. Fibrotic areas were observed in mice immunized with MyHC-α-loaded bmDCs 
boosted with CFA (I), but not in PBS treated animals (J). CFA boosting of mice 
immunized with OVA-loaded bmDCs failed to induce fibrosis (K). *p<0.05 by two-way 
ANOVA. Scale bar = 100µm. 
 
Figure 2 
 Characteristics of autoimmune myocarditis in MyD88-/- mice. 
Wild-type MyHC-α-loaded bmDCs induce a similar degree of myocarditis in wild-type 
(WT, A) and MyD88-/- (B) mice. Analysis of CD11b, Gr-1, F4/80, CD4 and CD11c 
expressing cells, gated on CD45+ heart infiltrates isolated from wild-type (solid bars) and 
MyD88-/- (open bars) mice at day 10 (C). Bars represent mean ± SD from at least 5 mice.  
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CD4+ T cells were isolated from spleens of wild-type (filled circles) and MyD88-/- (open 
circles) mice at day 10 and in vitro re-stimulated with MyHC-α peptide on irradiated 
syngeneic splenocytes (D). Data represent mean ± SD of triplicate samples from one 
representative out of four independent experiments.  
Cytokine production by splenic CD4+ T cells of WT (solid bars) and MyD88-/- (open 
bars) mice at day 0 and 10 (E). Bars represent mean ± SD from 3 mice.  
p>0.05 (n.s.) by the two-tailed Student’s t-test (C) and by two-way ANOVA (D,E). Scale 
bar = 100µm. 
 
Figure 3 
 MyD88 and IL-1 mediate fibrosis development. 
(A) Wild-type (WT), MyD88-/- and IL-1R-/- mice were immunized with MyHC-α-loaded 
bmDCs and challenged with PBS or CFA at day 10 and 17. 
(B) Wild-type mice were immunized with MyHC-α-loaded bmDCs and stimulated with 
PBS or recombinant IL-1β (20 µg/kg) at day 13, 17, 21 and 25. 
Fibrotic areas were scored on Masson’s trichrome stained heart sections at day 34. 
Individual values and the average for each group are shown. *p<0.05 by one-way 
ANOVA (A) and by the two-tailed Student’s t-test (B). 
 
Figure 4 
 MyD88-/- mice develop chronic myocarditis, but are protected from post-
inflammatory heart failure 
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Masson’s trichrome staining of heart sections of wild-type (WT, A,D) and MyD88-/- 
(B,E) mice immunized with MyHC-α-loaded bmDCs and challenged with MyHC-α/CFA 
at day 10 and 17. Both strains showed massive inflammation without detectable collagen 
deposition at day 21 (A,B). Myocarditis severity at day 21 was scored on heart sections 
stained with hematoxylin-eosin. Individual values and the median for each group are 
shown (C). However, wild-type but not MyD88-/- mice showed heart dilatation and 
massive fibrosis at day 42 (D,E). Heart/body weight (HW/BW) ratios (F) and fibrotic 
areas (G) scored on Masson’s trichrome stained heart sections at day 42 are presented for 
wild-type and MyD88-/- mice as individual values with the average for each group. 
p>0.05 (n.s.) by the two-tailed Mann-Whitney U test (C), *p<0.05 by the two-tailed 
Student’s t-test (F,G). Scale bar = 100µm. 
 
Figure 5 
 MyD88-/- mice are protected from impaired heart function.  
Echocardiography was performed on wild-type (WT, solid bars) and MyD88-/- (open 
bars) mice at day 0, and 42 days after disease induction with bmDCs and challenge with 
MyHC/CFA. Percent of fractional shortening (%FS, A) and percent of ejection fraction 
(%EF, B) represent measurements for cardiac contractility. E/A ratios (C) reflecting 
diastolic doppler tracings of mitral flow, and E`/A` ratios (D) reflecting mitral annulus 
velocity patterns represent readouts for diastolic function. E displays early, and A late 
diastolic inflow (mm/s). E` and A` correspond to early and late mitral annulus velocity 
(mm/s), respectively. In contrast to MyD88-/- mice, diseased wild-type mice show 
inversion of the E`/A` ratio and marked increase of the E/A ratio. These patterns indicate 
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impaired, restrictive diastolic filling. Data from one out of three experiments with similar 
results are shown. Data represent mean ± SD from 6 wild-type vs. 6 MyD88-/- mice. 
*p<0.05 by two-way ANOVA. 
 (E) Doppler tracing of diastolic mitral inflow. The left panel shows a normal tracing 
pattern in a wild-type mouse at day 0. The right panel exemplifies a restrictive pattern 
with a high E/A ratio in the same mouse with end stage heart failure 42 days after disease 
induction. 
 
Figure 6 
Resolution of inflammation is minimally depended on MyD88.  
Wild-type (WT) and MyD88-/- mice were immunized with MyHC-α-loaded bmDCs, 
challenged with PBS or CFA, and analyzed at day 21. 
(A) Myocarditis severity was scored on heart sections stained with hematoxylin-eosin. 
Individual values and the median for each group are shown. p>0.05 by the Kruskal-
Wallis one-way analysis. 
(B) Splenocytes were isolated and re-stimulated in vitro with MyHC-α peptide for 48 
hours. The data represent mean ± SD of triplicate culture wells from one representative 
out of two independent experiments. p>0.05 by two-way ANOVA. 
 
Figure 7 
Expression of profibrotic genes is MyD88- and IL-1-dependent. 
Wild-type (WT), MyD88-/- and IL-1R-/- mice were immunized with MyHC-α-loaded 
bmDCs and challenged with PBS or CFA. Real-Time RT-PCR was performed on heart 
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tissue lysates to assess the expression of pro-fibrotic genes at day 21. Bars represent mean 
± SD from at least 5 mice. *p<0.05 by one-way ANOVA. 
 
Figure 8 
Post-inflammatory heart pathology requires MyD88/IL-1 signalling in the 
BM-derived cell compartment. 
All chimeric mice were immunized with MyHC-α-loaded bmDCs and challenged with 
MyHC/CFA 6 weeks after BM reconstitution.  
(A-D) Analysis of chimeric mice reconstituted with EGFP+ BM. Flow cytometry analysis 
shows heart-infiltrating EGFP+ cells (A) expressing CD45 (B) at day 10 after 
immunization. Immunofluorescence analysis shows EGFP expression (D) in fibronectin-
positive (C) fibrotic cardiac tissue at day 42.  
(E,F) Fibronectin-producing cardiac fibroblasts expanded from fibrotic hearts (d42) of the 
chimeric mice reconstituted with EGFP+ BM (E), and of wild-type controls (F). 
 (G,H) Heart tissue sections of chimeric mice reconstituted with BM of the indicated 
donors were stained with Masson’s trichrome and analyzed for fibrosis at day 42 after 
immunization. Fibrotic areas (G) and heart/body weight (HW/BW) ratios (H) are 
presented as individual values with the average for each group. Scale bar = 20µm, WT – 
wild-type, *p<0.05 by one-way ANOVA. 
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